Cyclosporine-steroid combination therapy in 84 cadaveric renal transplants.
Sixty-three primary and 21 retransplant cadaver kidney allografts were placed in 77 patients over a one-year period with three- to six-month follow-up. Eight primary grafts (12.7%) and six retransplants (28.6%) were lost to rejection. Patient mortality was 3.9%. There were no grafts lost and no deaths due to opportunistic infections. Renal function at 6 months after transplantation was similar in all primary transplant recipients regardless of risk factors, including advanced age, diabetes, or the need for postoperative dialysis.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D001803:Blood Transfusion; D002102:Cadaver; D002648:Child; D003524:Cyclosporins / Q000009:adverse effects / Q000627:therapeutic use*; D048909:Diabetes Complications; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006085:Graft Survival / Q000187:drug effects*; D006801:Humans; D007165:Immunosuppression Therapy; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D011184:Postoperative Period; D011241:Prednisone / Q000627:therapeutic use*; D011300:Preoperative Care
D003524:Cyclosporins; D011241:Prednisone